|
||||||||
News & EventsEvents Calendar:....................................................................................................................................... News & Press Releases
InterveXion has been awarded a two year $3.9 million dollar grant entitled “Chimeric anti-methamphetamine Monoclonal Antibody for Treating Stimulant Toxcitiy” by the National Institutes of Health, National Institute on Drug Abuse (NIDA). W. Brooks Gentry, M.D. and R. Barry Holtz, Ph.D. are the principal investigators. This grant was part of the American Recovery and Reinvestment Act of 2009. This was a highly competitive pool and awards were given to institutions and companies that could show that the funds would accelerate programs toward a major milestone or commercialization endpoint. These funds will be focused on the scale-up of the methamphetamine mAb product and will produce cGMP compliant materials for a Phase I clinical trial. .......................................................................................................................................
InterveXion met with the agency on September 29, 2009 to discuss the planned upcoming Phase 1 clinical trial of the PCP antibody ch-mAb6B. InterveXion’s management team was present with its regulatory consultant from Quintiles Dr. Raj Kishore and members of the NIDA management group as attendees. The meeting clarified a series of questions that InterveXion posed to the agency. The meeting was extremely encouraging and there are no roadblocks to go forward with the filing of the IND. .......................................................................................................................................
Despite the fact that there are many political allusions to the title of this column, today’s words are about a fledgling business enterprise here in Arkansas. More importantly, they are about the life of a single mother who gives a new definition to “strength of mind.” A few weeks ago, UAMS researchers unveiled a start-up biotech company, now known as InterveXion, that could impact our state’s health and business landscape. InterveXion is an outgrowth of Arkansas Bioventures, the research and business incubator at the state’s well-known medical campus. The venture has its roots in Arkansas’ tobacco settlement funding. The Arkansas Biosciences Institute, a partnership of scientists from institutions including UAMS and the University of Arkansas at Fayetteville, was created by the voter-approved Tobacco Settlement Proceeds Act and it helped bring the researchers of InterveXion together in 2000 to focus their efforts. Before we die, you and I may look back someday and say, “InterveXion altered the course of society in a most dramatic way.” Here‘s how... read more.... .......................................................................................................................................
LITTLE ROCK - InterveXion Therapeutics, LLC, a company started in the biomedical business incubator at the University of Arkansas for Medical Sciences (UAMS), has received a $3 million grant to conduct clinical trials for the first antibody treatment for addiction to the drug known as phencyclidine, or PCP. The business development grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) will provide funding for five years to obtain Food and Drug Administration approval and conduct clinical trials on a protein-based therapy that may blunt the effects of phencyclidine. Michael Owens, Ph.D., director of the UAMS Center for Alcohol and Drug Abuse and a professor in the Department of Pharmacology and Toxicology in the UAMS College of Medicine, invented the addiction treatment. “Drug abuse is one of the nation's most serious health problems and has very few treatments... read more.... .......................................................................................................................................
LITTLE ROCK - A company run by University of Arkansas medical researchers has received a $3 million grant to conduct the first clinical trials of antibodies to basically neutralize the effects of the illicit drug known as angel dust. The four people who started InterveXion Therapeutics LLC and developed it in the University of Arkansas for Medical Sciences' biomedical incubator, announced the grant Thursday. The award comes from the National Institutes of Health's National Institute on Drug Addiction. The money will help researchers develop a vaccine they believe will be able to negate addiction to angel dust, the popular street name for phencyclidine, or PCP. They also are developing a similar addiction-busting injection for methamphetamine, the recreational, home-cooked drug that has gripped rural America, ... read more.... ....................................................................................................................................... |
||||||||
|
||||||||
